^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KUR-501

    i
    Other names: KUR-501, CMD-501, CAR-NKT therapy, CAR.GD2-IL-15 NKTs, Chimeric antigen receptors natural killer T-cells (CAR-NKT) therapy, GINAKIT cells, GD2-CAR, GD2-CAR NKT cells, CAR-modified NKT-cell therapy
    Associations

    News

    Trials
    Company:
    Athenex, Baylor College of Medicine, Texas Children’s Hospital
    Drug class:
    GD2 ganglioside inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (clinicaltrials.gov)
    P1, N=70, Recruiting, Baylor College of Medicine | Trial primary completion date: Jul 2025 --> Dec 2027
    Trial primary completion date
    |
    KUR-501
    11ms
    PRDM1 is a key regulator of the natural killer T-cell central memory program and effector function. (PubMed, Cancer Immunol Res)
    In contrast, shRNA-mediated PRDM1 knockdown preserved effector function while promoting central memory differentiation, resulting in GD2.CAR NKTs with potent in vivo antitumor activity. Thus, we have identified PRDM1 as a regulator of NKT memory differentiation and effector function that can be exploited to improve the efficacy of NKT-based cancer immunotherapies.
    Journal
    |
    GZMB (Granzyme B) • PRDM1 (PR/SET Domain 1)
    |
    KUR-501
    1year
    GINAKIT2: GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children with Neuroblastoma (clinicaltrials.gov)
    P1, N=54, Recruiting, Baylor College of Medicine | N=36 --> 54
    Enrollment change
    |
    KUR-501
    over2years
    Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. (PubMed, Nat Med)
    No dose-limiting toxicities occurred; one patient experienced grade 2 cytokine release syndrome that was resolved by tocilizumab. Additionally, their anti-tumor activity may be enhanced by targeting BTG1. ClinicalTrials.gov registration: NCT03294954 .
    P1 data • Journal
    |
    IL15 (Interleukin 15)
    |
    Actemra IV (tocilizumab) • KUR-501